US approves drug against rare type of blood cancer.

The US Food and Drug Administration (FDA) approves Eli Lilly for a form of rare blood cancer. The new drug is called Jaypirca.

This is stated on the company's website..

The drug has proven efficacy for patients with relapsed or refractory (refractory) mantle cell lymphoma. This is a rare type of blood cancer that starts as white blood cells in the lymph nodes and spreads aggressively to other parts of the body..

A professor at the University of Texas Cancer Center noted that the approval of this drug is an important advance for patients who have historically had a poor prognosis after stopping the standard phase of treatment..

He also said that the approval of the drug was preceded by clinical trials.. Of 120 early and intermediate patients, 50% responded to the drug and 13% achieved remission.

Patients with mantle cell lymphoma who have completed at least two cycles of chemotherapy are expected to be able to purchase the drug in the coming weeks. The wholesale cost will be 21 thousand US dollars per month for a dose of 200 mg.

https://newsyou. info/ keywords:.